Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation. Pfizer’s stock has declined 7.3% so far this year against an increase of 2.4% for the industry. PFE Stock Underperforms Industry.

Over the past decade, Pfizer has strengthened its R&D pipeline through M&A deals and clinical trial success. Pfizer’s key vaccine candidates in late-stage studies are its C. difficile vaccine and an ...

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...